Day One

• Defining where patient engagement can influence early asset optimization and preclinical planning
• Measuring insights that inform development strategy, target profiles, and outcome priorities
• Showcasing real-world examples where early patient data measurably improves Target Product and Target Value Profiles

Details TBA

• Identifying the earliest decision points – modality, feasibility, value drivers – where patient input can reshape scientific assumptions
• Creating practical, visible ways to capture “what changed” as a result of early insight, not just how many touchpoints occurred
• Demonstrating how early engagement has reshaped research hypotheses, program priorities, and go/no-go decisions before assets enter formal development

Join our speed networking session tailored for Patient Engagement professionals, like yourselves, to connect with fellow industry peers to facilitate rapid yet meaningful exchanges of insights and expertise. Elevate your networking experience during this session designed for impactful connections within the space.

• Lessons from embedding patient input early in oncology trial design, and how “starting with the end in mind” enables measurable outcomes
• Case reflections from KEYNOTE-355: tracking changes to study design, enrollment dynamics, and patient access outcomes
• Implementing pre–post insight evaluation tools across global teams to quantify what internal and external stakeholders view as meaningful impact
• Strategies for separating signal from noise when measuring impact in a complex trial environment with multiple confounders

• Applying patient feedback to optimize trial design, reduce participant burden, and improve feasibility before enrollment begins
• Quantifying design impact through measurable outcomes such as fewer protocol amendments, faster site activation, and better alignment with patient needs
• Demonstrating real-world ROI of early engagement by linking protocol adjustments to downstream trial efficiency and participant experience

• Tracking ongoing trial KPIs such as recruitment velocity, screen failures, retention, and site engagement to measure engagement impact in-flight
• Monitoring patient experience during the trial through feedback loops and digital tools to identify and address burden points promptly
• Showcasing mid-trial adjustments informed by patient input that measurably improve retention, adherence, and overall study performance

• Aligning PFDD and RWE across regulators, payers, and HTAs to build a unified, patient-centered evidence strategy that supports regulatory decisions and reimbursement requirements
• Demonstrating stakeholder impact through patient-driven evidence, quantifying benefit–risk, payer value, and HTA relevance using data that resonates across decision-makers
• Tracking KPIs that link patient engagement to regulatory and market success, showing improvements in submissions, launch readiness, payer value propositions, and time-to-market
• Embedding patient insights across evidence generation and access pathways, from trial design and labeling discussions to regulatory dossiers, HTA submissions, and global launch optimization

• Quantifying patient connection and activation through opt-in rates, sustained navigator engagement, and community-specific adoption trends
• Measuring educational impact using pre- and post-program analytics that capture increases in treatment awareness, confidence, and intention to initiate therapy
• Using compliant, aggregated CRM insights to track behavior change, treatment comprehension, and community-level patterns while navigating legal and data-sharing constraints
• Translating these insights into clear, evidence-based narratives that demonstrate value, secure leadership buy-in, and guide resourcing decisions for scalable patient-focused models

• Quantifying representation of diverse and underserved communities within patient engagement and clinical insight activities
• Integrating inclusive metrics into trial reporting to meet regulatory and ethical expectations for equitable participation
• Leveraging data to show how inclusive engagement improves recruitment, retention, and relevance of evidence packages

• Exploring what engagement metrics and KPIs matter most to patients and advocates based on their experiences in clinical research
• Discussing how patient and advocate input can guide the development of measurable outcomes for evaluating engagement success
• Sharing real-world examples and priorities from patients and advocates to inform actionable, evidence-based engagement strategies